Australian researchers have discovered how changes in antibody levels over time can predict which children are likely to outgrow their peanut allergy.
The research, led by Murdoch Children’s Research Institute (MCRI) and published in Allergy, found two thirds of children with a peanut allergy remain allergic by the age of 10. But for those who did naturally outgrow their allergy, the majority achieved this by six years old.
The study was the first to use antibodies as biomarkers to identify persistent or a resolved peanut allergy during the first 10 years of life in children who naturally outgrew it without clinical intervention.
A rise or drop in the levels of two antibodies (sIgG4 and sIgE) that respond to peanut allergens were key to determining allergy resolution. Changes in the blood test levels of these two antibodies were detected in children who naturally outgrew their allergy.
Antibody levels measured at diagnosis did not predict who would outgrow their peanut allergy, but changes in these levels over time revealed who was more likely to.
The study involved 156 infants in Melbourne with challenge-confirmed peanut allergy from the HealthNuts study who were followed up at ages four, six and 10 years with questionnaires, skin prick tests, blood tests and oral food challenges.
Peanut allergy resolved in a third of children by 10 years, with nearly all who outgrew it doing so by age four to six.
MCRI researcher Kayla Parker said the findings would help clinicians better identify which children were likely to have an ongoing peanut allergy and ensure they received ongoing education and management.
“Little was known before this research about whether antibodies could be used as biomarkers of naturally resolving peanut allergy during the primary school years,” she said.
“We found the longitudinal changes were more useful in predicting those children on the path to peanut allergy resolution than relying on a single snapshot at one timepoint.”
Ms Parker said regular review of children with a peanut allergy by their allergist was important to ensure they receive the most appropriate clinical care.
“Children allergic to peanut who have decreasing antibody markers may benefit from additional visits with their allergist to determine the right time for follow-up food challenges to confirm if their peanut allergy has resolved,” she said.
“Those with high or increasing levels of these biomarkers are less likely to spontaneously outgrow their peanut allergy and could be prioritised for potential early treatment options if available.
“Currently there is no routinely available treatment for peanut allergy and children should maintain strict peanut allergen avoidance, however innovative treatment options are available through clinical trials, which are listed on the National Allergy Centre of Excellence’s (NACE) Allergy Studies Directory.”
It comes as another new study, led by MCRI, found allergic diseases continue to be a significant public health burden in Australian children, with allergies affecting 40 per cent of primary school-aged children and a third having multiple allergies.
Published in The Journal of Allergy and Clinical Immunology: In Practice, the research reported 45 per cent of infants with a food allergy have persistent symptoms to age 10.
Between the ages of six and 10, asthma prevalence remained similar at around 13 per cent, eczema rates decreased from 15 per cent to 13 per cent while hay fever cases increased from 15 per cent to 25 per cent.
MCRI Associate Professor Rachel Peters said the research highlighted the importance of prevention and treatment strategies, particularly for nut allergies, as well as eczema, asthma and hay fever.
“Understanding how allergy prevalence varies across the school years has important implications on informing the burden of disease, allocating healthcare resources and improving school and workforce planning,” she said.
